Evolent Health - Q3 2026 Earnings Call - EVOLENT HEALTH INC

Explicit Guidance:

• FY 2026 Revenue: Reiterated range of $2.6 billion to $2.7 billion.
• FY 2026 Adjusted EBITDA: Raised guidance to $130 million to $135 million (previously $120M–$135M); midpoint target is $150 million or higher.
• Q4 2026 Adjusted EBITDA: Expecting a sequential increase of $11 million to $16 million (previously guided for $7M–$15M), driven by continued Medical Expense Ratio (MER) upside.
• FY 2026 MER: Reiterated full-year target of approximately 93%.
• FY 2026 Operating Expenses: Targeting adjusted cost of revenue (excluding medical claims, including medical devices) plus adjusted SG&A of approximately $675 million.
• FY 2026 Capital Expenditures: Expecting $26 million to $28 million total (previously $7M/quarter run-rate implied lower).
• FY 2026 Operating Cash Flow: Expecting $10 million to $20 million after approximately $60 million in annual cash interest expense, subject to timing of late December reconciliation payments.
• FY 2027 Adjusted EBITDA: Midpoint target of $150 million or higher remains the baseline for confidence, assuming no changes in legislative environment.
• FY 2027 Revenue: Strong growth expected driven by performance suite; specific range to be provided in February 2027.
• FY 2027 AI Capex: Expected to be higher than 2026 levels to support growth and efficiency.

Business-Segment Outlook:

• Performance Suite: Expected to remain the primary growth driver; Aetna and Highmark partnerships anticipated to contribute to margin improvement as they mature, with a full year of Highmark revenue recognized.
• Oncology: Anticipated to represent over 70% of Evaluant's (Evelyn) 2027 revenue. New oncology care model rolled out with American Oncology Network (AON) across 8 states serves as a blueprint for industry-wide friction reduction.
• Technology & Services: Expansion with a national payer effective November 1, 2026, adding 11 states (total footprint of 50 states, up from 39) and ~7 million lives.
• Member Navigation: First expansion with a client signed in Q3 adding ~1 million commercial lives, effective January 1, 2027; includes member navigation across existing and new lives.
• Surgical Management (IPG): Largest customer renewed for an additional four years, signaling long-term partner commitment.

Market and Competitive Outlook:

• AI Market Position: Management claims current market leadership in AI for specialty reviews; Auth Intelligence platform is expected to process >80% of manual prior authorizations (approx. 2 million cases) by end of 2027.
• Prior Authorization Efficiency: Auto-approval rates have improved by up to 20 percentage points (e.g., 60% to 80%) in deployed instances; 10% improvement reduces manual touches by ~600,000/year.
• Market Share: Aim to grow share of the 140+ million annual prior authorization volume in the U.S. (currently evaluating ~9 million).
• Competitive Landscape: Believes core offering is highly defensible with no direct competitors matching clinical depth and AI integration; expects to share savings with clients to drive market share and retention.
• Pricing & Margins: Pricing dynamics expected to stabilize in 2027; margin expansion driven by AI efficiency and contract maturation, though some savings will be shared with clients.

Macro / Industry Outlook:

• Legislative Environment: Current 2027 guidance assumes "status quo" with no changes to the "One Big Beautiful Bill."
• Political Risks/Opportunities: Potential rollback of Medicaid work requirements or exchange subsidies would have a "very significant positive impact"; potential "Medicare for All" legislation viewed as additional upside for membership volumes.
• Medicaid Trends: Membership attrition remains a headwind due to work requirements, with timing effects expected to be a variable.
• Health Plan Cycle: Noting an easing underwriting cycle for health plans, contributing to a more favorable renewal environment.
• Medical Cost Trends: Assuming stability over the next 12 months following stabilization from previous year declines; in-year favorable development from completed Q1 claims run-out has already driven Q3 MER improvement.

Strategic Initiatives:

• Auth Intelligence Platform: Targeting deployment to 2 million cases (80% of manual volume) by end of 2027; expecting returns to begin in late 2027 via cost reductions, with further returns in 2028+ from operating cost efficiency and new product launches.
• Debt Reduction: Targeting deployment of up to $50 million toward reducing outstanding indebtedness by end of 2026.
• Capital Allocation: Prioritizing margin and cash generation over aggressive revenue growth; maintaining flexibility on debt refinancing and capital market alternatives over the next 12–24 months.
• Product Launches: Hosting national webinar in January to update on AI innovations and oncology product enhancements; new cancer care model launched with AON.
• EMR Integration: Embedding clinical pathways directly into EMRs of leading oncology groups.

Risks and Headwinds to Outlook:

• Membership Attrition: Primary risk is Medicaid work requirements and subplan client attrition in administrative services.
• Scope Adjustments: Contract renewals and extensions may lead to scope reductions.
• Investment Timing: Near-term costs associated with high-return investments (e.g., AI Capex) will offset some returns in the short term.
• Legislative Uncertainty: Changes to the "One Big Beautiful Bill" or Medicaid work requirements could materially impact revenue and EBITDA trajectories.
• Cash Flow Timing: Q4 operating cash flow subject to timing of reconciliation payments expected in late December.
• MER Variance: Sequential MER improvement expected to be smaller in Q4 as some benefits flowed through in Q3; Q3 benefit was larger than typical due to earlier-than-expected claims run-out.

Management Tone on the Future:

• Confidence: High degree of confidence in achieving $150M+ EBITDA midpoint for 2027, driven by the combination of MER performance and AI-driven cost reductions in the second half of 2027.
• Strategic Shift: Noted a shift from growth-at-all-costs to a discipline of prioritizing margin and cash generation, enabled by a portfolio of maturing contracts.
• Customer Trust: Positive tone regarding customer willingness to expand scope (adding member navigation) and renew multi-year contracts.
• AI Moat: Expressed strong conviction that AI capabilities provide a "self-reinforcing loop" and data moat that will drive differentiation and share expansion.

Miscellaneous:

• Q2/Q3 Comparison: Q3 revenue was $725M (+11% QoQ); Adjusted EBITDA was $34M (+22% QoQ). MER improved 220 bps sequentially to 93%.
• Cash & Liquidity: Ended Q3 with $148M unrestricted cash and $776M net debt.
• AI Capex Specifics: No specific dollar amount given for 2027 AI Capex, but confirmed it will exceed 2026 levels.
• Product Naming: "Off Intelligence" appears to be a transcription error for "Auth Intelligence" in the source text; corrected contextually.
• Company Name: Transcript references both "Evelyn" and "Evalent/Evaluant" interchangeably; likely "Evalent" is the correct entity name.